Summary
The present investigation was conducted to document the serum concentrations of immunosuppressive acidic protein (IAP) in patients with intracranial tumours utilizing the single radial immunodiffusion method. Among 46 pre-operative patients, elevated serum levels of IAP were found in nine of 16 patients with gliomas, six of nine patients with metastasis, and two of 21 patients with non-glial, histologically benign intracranial tumours. The mean value of serum IAP in glial or metastatic tumours was found significantly higher than that of either non-glial or normal individuals. It was postulated that serum IAP levels could correlate with a grade of anaplasia and malignancy of the tumour. And it was also of note that serum IAP levels appeared to have a tendency to decrease in response to the treatment. In addition, serum IAP levels were found correlated with the clinical condition and course of disease as evaluated by performance status and erythrocyte sedimentation rate. Therefore, it was suggested that measurement of serum IAP could be, at least in part, useful in validating the histologic analysis of brain tumours, in following responses to treatment when used as a tumour indicator, and in monitoring the progress of the disease in patients in terms of performance status.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Allen JC, Nisselbaum J, Epstein F, Rosen G, Schwartz MK (1979) Alphafetoprotein and human chorionic gonadotropin determination in cerebrospinal fluid. An aid to the diagnosis and management of intracranial germ-cell tumors. J Neurosurg 51: 368–374
Baskies AM, Chretien PB, Weiss JF, Beveridge RA, Mauch R, Trahan EE, Catalona WJ (1978) Serum Levels of a HS-glycoprotein and acute-phase proteins correlate with cellular immunity in cancer patients. Proc Am Assoc Cancer Res 19: 221
Bradley WP, Blasco AP, Weiss JF, Alexander JC Jr, Silverman NA, Chretien PB (1977) Correlations among serum protein-bound carbohydrates, serum glycoproteins, and tumor burden in cancer patients. Cancer 40: 2264–2272
Brooks WH, Caldwell HD, Mortara RH (1974) Immune responses in patients with gliomas. Surg Neurol 2: 419–423
Brooks WH, Netsky MG, Normansell DE, Horwitz DA (1972) Depressed cell-mediated immunity in patients with primary intracranial tumors: Characterization of a humoral immunosup-pressive factor. J Exp Med 136: 1631–1647
Cheresh DA, Distasio JA, Vogel CL, Lopez DM (1982) Mitogen-induced blastogenesis and receptor mobility inhibition by breast cancer with elevated orosomucoid (α1acid glycoprotein) levels. JNCI 68: 779–783
Ganz PA, Shell WE, Tokes ZA (1983) Evaluation of a radioimmunoassay for α1acid glycoprotein to monitor therapy of cancer patients. JNCI 71: 25–30
Harvey HA, Lipton A, Serra DA, Albright C, DeLong S, Davidson EA (1978) Inhibition of in vitro lymphocyte function by α1acid glycoprotein, tumor related glycoprotein and fibrinogen degeneration products. Proc Am Assoc Cancer Res 19: 24
Harvey HA, Lipton A, White D, Davidson E (1981) Glycoprotein and human cancer: II Correlation between circulating level and disease status. Cancer 47: 324–327
Hayakawa T, Morimoto K, Ushio Y, Mori T, Yoshimine T, Myoga A, Mogami H (1980) Levels of astroprotein (an astrocyte-apecific cerebroprotein) in cerebrospinal fluid of patients with brain tumors. An attempt at immunochemical diagnosis of gliomas. J Neurosurg 52: 229–233
Horton J, Schoenfeld D (1982) Chemotherapy for malignant gliomas. In: Chang CHet al (eds) Tumors of the central nervous system: Modern radiotherapy in multidisciplinary management. Masson Publishing USA Inc, New York, pp 47–55
Ishida N, Tamura K, Shibata Y (1980) The characterization of immunosuppressive acidic protein (IAP) and its diagnostic evaluation (in Japanese). Igaku No Ayumi 115: 423–433
Israel L, Edelstein R (1978) In vivo and in vitro studies on nonspecific blocking factors of host origin in cancer patients. Israel J Med Sci 14: 105–130
Kikuchi K, Neuwelt EA (1983) Presence of immunosuppressive factors in brain-tumor cyst fluid. J Neurosurg 59: 790–799
Kock TR, Lichtenfeld KM, Wiernik PH (1983) Detection of central nervous system metastasis with cerebrospinal fluid beta-2-microglobulin. Cancer 52: 101–104
Kurman RJ, Scardino PT, McIntire KR, Waldmann TA, Javadpour N (1977) Cellular localization of alpha-fetoprotein and human chorionic gonadotropin in germ cell tumors of the testis using an indirect immunoperoxidase technique. A new approach to classification utilizing tumor markers. Cancer 40: 2136–2151
Mancini G, Carbonara AP, Hermans JE (1965) Immuno-chemical quantitation of antigen by single immunodiffusion. Immunochemistry 2: 235–254
Matsuura H, Nakazawa S (1985) Prognostic significance of serum α1-acid glycoprotein in patients with glioblastoma multiforme: a preliminary communication. J Neurol Neurosurg Psychiatr 48: 835–837
Roboz E, Hess WC, Foster FM (1955) Determination of serum proteins and polysaccharides. Comparison of neoplastic diseases, particularly of the central nervous system. Arch Neurol Psychiatr 73: 536–543
Roszman TL, Brooks WH (1980) Immunobiology of primary intracranial tumours. III. Demonstration of a qualitative lymphocyte abnormality in patients with primary brain tumours. Clin Exp Immunol 39: 395–402
Sawada M, Okudaira Y, Matsui Y, Schimizu Y (1983) Immuno-suppressive acidic protein in patients with ovarian cancer. Cancer 52: 2081–2085
Sawada M, Okudaira Y, Matsui Y, Schimizu Y (1984) Immuno-suppressive acidic protein in patients with gynecologic cancer. Cancer 54: 652–656
Sawaya R, Cummins CJ, Smith BH, Kornblith PL (1985) Plasma fibronectin in patients with brain tumors. Neurosurgery 16: 161–165
Shibata Y, Tamura K, Ishida N (1983) In vivo analysis of the suppressive effects of immunosuppressive acidic protein, a type of α1-acid glycoprotein, in connection with its high level in tumor-bearing mice. Cancer Res 43: 2889–2896
Stolinsky DC (1981) Prolonged survival after cerebral metastasis of testicular carcinoma. Cancer 47: 978–981
Suzuki Y, Tanaka R (1980) Carcinoembryonic antigen in patients with intracranial tumors. J Neurosurg 53: 355–360
Talerman A, Haije WG (1974) Alphafetoprotein and germ cell tumors: a possible role of yolk sac tumor in production of alpha-fetoprotein. Cancer 34: 1722–1726
Tamura K, Shibata Y, Matsuda Y, Ishida N (1981) Isolation and characterization of an immunosuppressive acidic protein from ascitic fluids of cancer patients. Cancer Res 41: 3244–3252
Tanaka R, Sobue H (1983) Immunology of brain tumors: immunological situation of the brain. Brain Nerve (Tokyo) 35: 451–459
Thomas DGT, Lannigan CB, Behan PO (1975) Impaired cell-mediated immunity in human brain tumors. Lancet 1: 1389–1390
Thompson DK, Haddow JE, Smith DE, Ritchie RF (1983) Elevated serum acute phase protein levels as predictors of disseminated breast cancer. Cancer 51: 2100–2104
Weiss JF, Morants RA, Bradley WP, Chretien PR (1979) Serum acute-phase proteins and immunoglobulins in patients with gliomas. Cancer Res 39: 542–544
Walker C, Gray BN (1983) Acute-phase reactant proteins and carcinoembryonic antigen in cancer of the colon and rectum. Cancer 52: 150–154
Young HF, Sakalas R, Kaplan AM (1976) Immunologic depression in cerebral gliomas. In: Thompson RAet al (eds) Advances in neurology, vol 15. Raven Press, New York, pp 327–335
Author information
Authors and Affiliations
Additional information
This work was supported by Grant-in-aid for Scientific Research sponsered by Ministry of Education in Japan (Grant C-60570658).
Rights and permissions
About this article
Cite this article
Kikuchi, K., Gotoh, H. & Kowada, M. Immunosuppressive acidic protein in patients with brain tumours: A preliminary report. Acta neurochir 86, 42–49 (1987). https://doi.org/10.1007/BF01419503
Issue Date:
DOI: https://doi.org/10.1007/BF01419503